These drugs also appear to have major pleiotropic effects in CV risk reduction, (STEP trials , SELECT trial, STEP HFpEF, SCRIBE, SUMMIT, SURMOUNT-MMO (completion 2027)) reversal of metabolic dysfunctionassociated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (SYNERGY NASH MASH), and non-progression if not reversal of chronic kidney disease (CKD) (FLOW trial)
While genetic predisposition does not predict exact medication response, understanding your genetic profile may support a more informed conversation with your provider about the importance of medication stability and appropriate dosing for your metabolic profile
Medical weight loss injections are designed to address biological factors that affect hunger and metabolism, making them a valuable option for patients who have not achieved lasting success through diet and exercise alone
For these reasons, precursors of GSH have been investigated
(2016) 150:126279.e2